Insights on the Pyelonephritis Drug Market to 2022 | Industry Statistics, Emerging Demands, Forecast to 2028
The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea and vomiting, back, side, and groyne discomfort, and painful urination are all signs or symptoms of pyelonephritis, which might vary based on age. Kidney stones, a weaker immune system, anatomical abnormalities with the urinary tract, urine reflux issues, and nerve damage surrounding the bladder are all some factors that cause pyelonephritis. Owing to the high prevalence and incidence rates of pyelonephritis problems around the world, the global pyelonephritis treatment market is expected to rise rapidly during the forecast period. Each year, over 200,000 hospitalizations for acute pyelonephritis are reported in the US. As a result, the global pyelonephritis treatment market is likely to be driven by a huge population base with a kidney infection during the forecast period.
To Request a Sample of our Report on Pyelonephritis Drug
Market: https://www.omrglobal.com/request-sample/pyelonephritis-drug-market
The key companies operating in the industry are highly inclined towards the
adoption of different growth strategies including partnerships and
collaborations, mergers and acquisitions, geographical expansion, and new
product launches, to remain competitive in the marketplace. For instance, in
October 2021, Spero Therapeutics, Inc., a multi-asset clinical-stage
biopharmaceutical company focused on identifying, developing, and
commercializing treatments for multi-drug resistant bacterial infections and
rare diseases, announced that it has submitted a new drug application (NDA) to
the US Food and Drug Administration (FDA) for approval of tebipenem HBr tablets
for the treatment of complicated urinary tract infections (cUTI) including
pyelonephritis, caused by susceptible microorganisms.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Product Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Merck & Co, Inc., and AstraZeneca plc, among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Pyelonephritis Drug Market is Available @ https://www.omrglobal.com/industry-reports/pyelonephritis-drug-market
Global Pyelonephritis Drug Market Report by Segment
By Product Type
·
Finafloxacin
·
Fosfomycin Tromethamine
·
Nacubactam
·
Plazomicin Sulfate
·
Others
By Application
·
Hospital
·
Clinic
·
Others
Global Pyelonephritis Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment